Online first
Review paper
Published online: 2024-05-31

open access

Page views 128
Article views/downloads 81
Get Citation

Connect on Social Media

Connect on Social Media

Double hit — bispecific antibodies in cancer therapy

Alicja Bogdanowicz1, Kamila Wojas-Krawczyk1, Natalia Krzyżanowska1, Paweł Krawczyk1

Abstract

Immunotherapy has emerged as a promising strategy for cancer treatment, with bispecific antibodies (BsAbs) demonstrating significant therapeutic potential. BsAbs are biological molecules capable of simultaneously binding to two distinct antigens, allowing the immune response to target cancer cells precisely. However, despite promising results in preclinical studies and early clinical trials, immunotherapy based on these antibodies faces several significant issues that require careful consideration. One of them is the development of therapy resistance, which often leads to a loss of treatment effectiveness. Another challenge is the associated toxicity of immunotherapy. While BsAbs are designed to limit adverse effects, there remains a risk of side effects that can impact the quality of life for patients. Furthermore, it should be noted that the production of BsAbs is burdened with significant costs and involves complex processes, negatively affecting the accessibility of this therapy for the majority of patients. Hence, continuous efforts are necessary to develop more efficient and cost-effective methods for producing these antibodies to enable a broader range of patients to benefit from this innovative therapy.

Article available in PDF format

View PDF Download PDF file

References

  1. Khosla AA, Jatwani K, Singh R, et al. Bispecific Antibodies in Lung Cancer: A State-of-the-Art Review. Pharmaceuticals (Basel). 2023; 16(10).
  2. Labrijn AF, Janmaat ML, Reichert JM, et al. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019; 18(8): 585–608.
  3. Ueda A, Umetsu M, Nakanishi T, et al. Chemically Crosslinked Bispecific Antibodies for Cancer Therapy: Breaking from the Structural Restrictions of the Genetic Fusion Approach. Int J Mol Sci. 2020; 21(3).
  4. Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017; 9(2): 182–212.
  5. Zhukovsky EA, Morse RJ, Maus MV. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol. 2016; 40: 24–35.
  6. Lameris R, de Bruin RCG, Schneiders FL, et al. Bispecific antibody platforms for cancer immunotherapy. Crit Rev Oncol Hematol. 2014; 92(3): 153–165.
  7. Niewoehner J, Bohrmann B, Collin L, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014; 81(1): 49–60.
  8. Kontermann R. Dual targeting strategies with bispecific antibodies. mAbs. 2014; 4(2): 182–197.
  9. Wei J, Yang Y, Wang G, et al. Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol. 2022; 13: 1035276.
  10. Krah S, Kolmar H, Becker S, et al. Engineering IgG-Like Bispecific Antibodies-An Overview. Antibodies (Basel). 2018; 7(3).
  11. Dutta S, Ganguly A, Chatterjee K, et al. Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors. Biology (Basel). 2023; 12(2).
  12. Seifert O, Rau A, Beha N, et al. Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules. MAbs. 2019; 11(5): 919–929.
  13. Sedykh SE, Prinz VV, Buneva VN, et al. Bispecific antibodies: design, therapy, perspectives. Drug Des Devel Ther. 2018; 12: 195–208.
  14. Ahmad ZA, Yeap SK, Ali AM, et al. scFv antibody: principles and clinical application. Clin Dev Immunol. 2012; 2012: 980250.
  15. Surowka M, Schaefer W, Klein C. Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. MAbs. 2021; 13(1): 1967714.
  16. Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015; 67(2 Pt A): 95–106.
  17. Doppalapudi VR, Huang J, Liu D, et al. Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A. 2010; 107(52): 22611–22616.
  18. Li H, Er Saw P, Song E. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Cell Mol Immunol. 2020; 17(5): 451–461.
  19. Shatz W, Chung S, Li B, et al. Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity. MAbs. 2013; 5(6): 872–881.
  20. Tiller KE, Tessier PM. Advances in Antibody Design. Annu Rev Biomed Eng. 2015; 17: 191–216.
  21. Kontermann R, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015; 20(7): 838–847.
  22. Ayyar BV, Arora S, O'Kennedy R. Coming-of-Age of Antibodies in Cancer Therapeutics. Trends Pharmacol Sci. 2016; 37(12): 1009–1028.
  23. Lum LG, Thakur A, Liu Q, et al. CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2013; 19(6): 925–933.
  24. Iams WT, Sosman JA, Chandra S. Novel Targeted Therapies for Metastatic Melanoma. Cancer J. 2017; 23(1): 54–58.
  25. Boudousquie C, Bossi G, Hurst J, et al. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells. Immunology. 2017; 152(3): 425–438.
  26. Bossi G, Buisson S, Oates J, et al. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. Cancer Immunol Immunother. 2014; 63(5): 437–448.
  27. Pang X, Ma F, Zhang P, et al. Treatment of Human B-Cell Lymphomas Using Minicircle DNA Vector Expressing Anti-CD3/CD20 in a Mouse Model. Hum Gene Ther. 2017; 28(2): 216–225.
  28. Freedman JD, Hagel J, Scott EM, et al. Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies. EMBO Mol Med. 2017; 9(8): 1067–1087.
  29. Chen Y, Xu Y. Pharmacokinetics of Bispecific Antibody. Current Pharmacology Reports. 2017; 3(3): 126–137.
  30. Klein C, Schaefer W, Regula JT. The use of CrossMAb technology for the generation of bi- and multispecific antibodies. MAbs. 2016; 8(6): 1010–1020.
  31. Klein C, Sustmann C, Thomas M, et al. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs. 2012; 4(6): 653–663.
  32. Dengl S, Wehmer M, Hesse F, et al. Aggregation and chemical modification of monoclonal antibodies under upstream processing conditions. Pharm Res. 2013; 30(5): 1380–1399.
  33. Wan Y, Wang Y, Zhang T, et al. Application of pH-salt dual gradient elution in purifying a WuXiBody-based bispecific antibody by MMC ImpRes mixed-mode chromatography. Protein Expr Purif. 2021; 181: 105822.
  34. Shim H. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations. Biomolecules. 2020; 10(3).
  35. Klein C, Brinkmann U, Reichert JM, et al. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024; 23(4): 301–319.
  36. Krishnamurthy A, Jimeno A. Bispecific antibodies for cancer therapy: A review. Pharmacol Ther. 2018; 185: 122–134.
  37. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012; 12(4): 278–287.
  38. Mau-Sørensen M, Dittrich C, Dienstmann R, et al. A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3. Cancer Chemother Pharmacol. 2015; 75(5): 1065–1073.
  39. Tsikouras P, Tsagias N, Pinidis P, et al. The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature. Arch Gynecol Obstet. 2013; 288(3): 581–585.
  40. Fossati M, Buzzonetti A, Monego G, et al. Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM×anti-CD3). Gynecol Oncol. 2015; 138(2): 343–351.
  41. Ott MG, Marmé F, Moldenhauer G, et al. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int J Cancer. 2012; 130(9): 2195–2203.
  42. Kantarjian HM, Stein AS, Bargou RC, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014; 32(36): 4134–4140.
  43. Kantarjian HM, Stein AS, Bargou RC, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014; 32(36): 4134–4140.
  44. Nuñez-Prado N, Compte M, Harwood S, et al. The coming of age of engineered multivalent antibodies. Drug Discov Today. 2015; 20(5): 588–594.
  45. Wu J, Fu J, Zhang M, et al. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol. 2015; 8: 104.
  46. Goebeler ME, Bargou R. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Leuk Lymphoma. 2016; 57(5): 1021–1032.
  47. Aldoss I, Song J, Stiller T, et al. Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2017; 92(9): 858–865.
  48. Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012; 119(26): 6226–6233.
  49. Topp MS, Gökbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012; 120(26): 5185–5187.
  50. Zhou C, Tang KJ, Cho BC, et al. PAPILLON Investigators. Amivantamab plus Chemotherapy in NSCLC with Exon 20 Insertions. N Engl J Med. 2023; 389(22): 2039–2051.
  51. Gerard C, Shum B, Nathan P, et al. Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond. Immunooncol Technol. 2023; 19: 100386.
  52. Brazel D, Nagasaka M. The development of amivantamab for the treatment of non-small cell lung cancer. Respir Res. 2023; 24(1): 256.
  53. Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis. Mol Cancer Ther. 2020; 19(10): 2044–2056.
  54. Passaro A, Wang J, Shah S, et al. MARIPOSA-2 Investigators. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024; 35(1): 77–90.
  55. Nathan P, Hassel JC, Rutkowski P, et al. IMCgp100-202 Investigators. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021; 385(13): 1196–1206.
  56. Synoradzki KJ, Paduszyńska N, Solnik M, et al. From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma. Curr Oncol. 2024; 31(2): 778–800.
  57. Cho BC, Lee JS, Wu YL, et al. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial. J Thorac Oncol. 2023; 18(12): 1731–1742.
  58. Crescioli S, Kaplon H, Chenoweth A, et al. Antibodies to watch in 2024. MAbs. 2024; 16(1): 2297450.
  59. Ten Haaft BH, Pedregal M, Prato J, et al. Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives. Eur J Cancer. 2024; 199: 113564.
  60. Kaplon H, Crescioli S, Chenoweth A, et al. Antibodies to watch in 2023. MAbs. 2023; 15(1): 2153410.
  61. Li Q, Liu J, Zhang Q, et al. The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial. Nat Commun. 2024; 15(1): 1015.
  62. Michot JM, Koh Y, Lee P, et al. PB2102: PHASE 2 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLAMOTAMAB COMBINED WITH TAFASITAMAB (TAFA) + LENALIDOMIDE (LEN) VS TAFA+LEN IN RELAPSED OR REFRACTORY DLBCL. HemaSphere. 2022; 6: 1973–1974.
  63. Jiang Y, Wu S, Li R, et al. Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium. Exp Hematol Oncol. 2023; 12(1): 68.
  64. Luke JJ, Patel MR, Blumenschein GR, et al. The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med. 2023; 29(11): 2814–2824.
  65. MEDI5752 Suppresses Two Immune Checkpoints. Cancer Discov. 2022; 12(6): 1402.
  66. FDA. Guidance for industry: bispecific antibody development programs 2021. https://www.fda.gov/media/123313/download (09.01.2024).
  67. Ma J, Mo Y, Tang M, et al. Bispecific Antibodies: From Research to Clinical Application. Front Immunol. 2021; 12: 626616.
  68. Suurs FV, Lub-de Hooge MN, de Vries EGE, et al. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacol Ther. 2019; 201: 103–119.
  69. Rosenberg AS, Sauna ZE. Immunogenicity assessment during the development of protein therapeutics. J Pharm Pharmacol. 2018; 70(5): 584–594.
  70. Yu L, Xue Li, Liu F, et al. The applications of deep learning algorithms on in silico druggable proteins identification. J Adv Res. 2022; 41: 219–231.
  71. Joubert MK, Deshpande M, Yang J, et al. Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics. PLoS One. 2016; 11(8): e0159328.
  72. Cohen S, Myneni S, Batt A, et al. Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells. MAbs. 2021; 13(1): 1898831.
  73. Walsh RE, Lannan M, Wen Yi, et al. assessment of the immunogenicity of three antibodies reveals distinct immune stimulatory mechanisms. MAbs. 2020; 12(1): 1764829.
  74. Lin J, Lee SL, Russell AM, et al. A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeutics. PLoS One. 2021; 16(7): e0254944.
  75. Kroenke MA, Barger TE, Hu J, et al. Immune Complex Formation Is Associated With Loss of Tolerance and an Antibody Response to Both Drug and Target. Front Immunol. 2021; 12: 782788.
  76. Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017; 76(10): 1679–1687.
  77. Bar-Yoseph H, Pressman S, Blatt A, et al. Israeli IBD Research Nucleus. Infliximab-Tumor Necrosis Factor Complexes Elicit Formation of Anti-Drug Antibodies. Gastroenterology. 2019; 157(5): 1338–1351.e8.
  78. Holland MC, Wurthner JU, Morley PJ, et al. Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1. J Clin Immunol. 2013; 33(7): 1192–1203.
  79. Davda J, Declerck P, Hu-Lieskovan S, et al. Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. J Immunother Cancer. 2019; 7(1): 105.
  80. You G, Won J, Lee Y, et al. Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies. Vaccines (Basel). 2021; 9(7).
  81. Nie S, Wang Z, Moscoso-Castro M, et al. Biology drives the discovery of bispecific antibodies as innovative therapeutics. Antib Ther. 2020; 3(1): 18–62.
  82. Kuriakose A, Chirmule N, Nair P. Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications. J Immunol Res. 2016; 2016: 1298473.
  83. Guidance for industry: immunogenicity assessment for therapeutic protein products. Federal Register. 2014; 79(157): 47649–47650. https://www.govinfo.gov/content/pkg/FR-2014-08-14/pdf/2014-19267.pdf (09.01.2024).
  84. Hamuro L, Kijanka G, Kinderman F, et al. Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins. J Pharm Sci. 2017; 106(10): 2946–2954.
  85. Zhu M, Wu B, Brandl C, et al. Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications. Clin Pharmacokinet. 2016; 55(10): 1271–1288.
  86. Yu S, Li A, Liu Q, et al. Recent advances of bispecific antibodies in solid tumors. J Hematol Oncol. 2017; 10(1).
  87. Saber H, Del Valle P, Ricks TK, et al. An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection. Regul Toxicol Pharmacol. 2017; 90: 144–152.
  88. Schlegel P, Lang P, Zugmaier G, et al. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica. 2014; 99(7): 1212–1219.
  89. Wolach O, Stone RM. Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2015; 21(19): 4262–4269.
  90. Sheppard M, Laskou F, Stapleton PP, et al. Tocilizumab (Actemra). Hum Vaccin Immunother. 2017; 13(9): 1972–1988.
  91. Amgen Inc. BLINCYTO® (Blinatumomab) for Injection, for Intravenous Use: US Prescribing Information. 40.
  92. Mortezaee K, Majidpoor J. Reinstating immunogenicity using bispecific anti-checkpoint/agent inhibitors. Biomed Pharmacother. 2023; 162: 114621.
  93. De Velasco G, Je Y, Bossé D, et al. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res. 2017; 5(4): 312–318.
  94. Puzanov I, Diab A, Abdallah K, et al. Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017; 5(1): 95.
  95. Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol. 2018; 4(2): 173–182.
  96. Yin Q, Wu L, Han L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023; 14: 1167975.
  97. Wang DY, Salem JE, Cohen JV, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018; 4(12): 1721–1728.
  98. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021; 39(36): 4073–4126.
  99. Thakur A, Huang M, Lum LG. Bispecific antibody based therapeutics: Strengths and challenges. Blood Rev. 2018; 32(4): 339–347.
  100. Kang J, Sun T, Zhang Y. Immunotherapeutic progress and application of bispecific antibody in cancer. Front Immunol. 2022; 13: 1020003.